CN Patent

CN112654356A — 增加四氢生物蝶呤血浆暴露的组合物和方法

Assigned to Ptc Medical Mp Co · Expires 2021-04-13 · 5y expired

What this patent protects

本发明的特点在于包含墨蝶呤或其药学上可接受的盐的组合物，以及用于治疗BH4相关病症的方法。在一些实施方案中，这些组合物和方法导致BH4的血浆暴露的增加。

USPTO Abstract

本发明的特点在于包含墨蝶呤或其药学上可接受的盐的组合物，以及用于治疗BH4相关病症的方法。在一些实施方案中，这些组合物和方法导致BH4的血浆暴露的增加。

Drugs covered by this patent

Patent Metadata

Patent number
CN112654356A
Jurisdiction
CN
Classification
—
Expires
2021-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Ptc Medical Mp Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.